What Does Failure After Surgery or Radiation Mean?

European Urology, Supplements

Volumn 7, Issue 5, 2008, Pages 410-415

  Clarke, Noel W ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

ASTRO 2006 definition; Postprostatectomy failure; Prostate cancer; Radiation failure; Rising PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; HUMAN; MORBIDITY; PELVIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SEMINAL VESICLE; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 44549086713     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.01.017     Document Type: Review

References (34)

1. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
2. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007) 540-545
3. Stone N.N., Stock R.G., White I., and Unger P. Patterns of local failure following prostate brachytherapy. J Urol 177 (2007) 1759-1763
4. Roscogno M., Cozzorini C., Scattoni V., et al. A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. Radiother Oncol 82 (2007) 30-37
5. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in post-prostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
6. Buyyounouski M.K., Hanlon A.L., Horwitz E.M., and Pollack A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 59-66
7. Zhou P., Chen M.H., McLeod D., Carroll P.R., Moul J.W., and D'Amico A.V. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992-6998
8. Maffezzini M., Bossi A., and Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol 51 (2007) 605-613
9. Toledano A., Chauveinc L., Flam T., et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure. Cancer Radiother 11 (2007) 105-110
10. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
11. Han M., Partin A.W., Pound C.R., Epstein J.I., and Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
12. Zincke H., Oesterling J.E., Blute M.L., Bergstralh E.J., Myers R.P., and Barrett D.M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850-1857
13. Kupelian P.A., Katcher J., Levin H.S., and Klein E.A. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37 (1997) 1043-1052
14. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
15. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
16. Parker C., Muston D., Melia J., Moss S., and Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Canc 94 (2006) 1361-1368
17. Stephenson A.J., Scardino P.T., Bianco F.J., et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 172 (2004) 2239-2243
18. Ismail M., Ahmed S., Kastner C., and Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 100 (2007) 760-764
19. Nguyen P.L., D'Amico A.V., Lee A.K., and Suh W.W. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110 (2007) 1417-1428
20. Morris S.L., Parker C., Huddart R., Horwich A., and Dearnaley D. Current opinion on adjuvant and salvage treatment after radical prostatectomy. Clin Oncol (R Coll Radiol) 16 (2004) 277-282
21. Lee L.W., Clarke N.W., Ramani V.A., Cowan R.A., Wylie J.P., and Logue J.P. Adjuvant and salvage treatment after radical prostatectomy: current practice in the UK. Prostate Cancer Prostatic Dis 8 (2005) 229-234
22. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 366 (2005) 524-525
23. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
24. Parker C., Sydes M., Catton C., et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase 3 trial of adjuvant treatment after radical prostatectomy. BJU Int 99 (2007) 1376-1379
25. Eulau S.M., Tate D.J., Stamey T.A., Bagshaw M.A., and Hancock S.L. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41 (1998) 735-740
26. King C.R., Presti Jr. J.C., Gill H., Brooks J., and Hancock S.L. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys 59 (2004) 341-347
27. Katz M.S., Zelefsky M.J., Venkatraman E.S., Fuks Z., Hummer A., and Leibel S.A. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21 (2003) 483-489
28. Radiation Therapy Oncology Group. A phase III trial of radiation therapy with or without Casodex in patients with PSA elevation following radical prostatectomy for pT3N0 carcinoma of the prostate. Available at: http://www.rtog.org/members/protocols/96-01/96-01.pdf. Accessed 2006.
29. See W., Iversen P., Wirth M., McLeod D., Garside L., Morris T., and Hammerer P.G. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol 44 (2003) 512-518
30. Tyrrell C.J., and 'Casodex' Early Prostate Cancer Trialists Group. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 76 (2005) 4-10
31. Herr H.W., Kornblith A.B., and Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71 (1993) 1143-1150
32. Herr H.W., and O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 163 (2000) 1743-1746
33. Smith MR, Lee WC, Krupsi T, et al. Association between androgen deprivation therapy and fracture risk: a population-based cohort study in men with non-metastatic prostate cancer. Proc Am Soc Clin Oncol 2004 (abstract no. 4507).
34. Shahinian V.B., Kuo Y.-F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation therapy for prostate cancer. N Engl J Med 352 (2005) 154-164